These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27754848)

  • 1. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature.
    Gilles ME; Maione F; Cossutta M; Carpentier G; Caruana L; Di Maria S; Houppe C; Destouches D; Shchors K; Prochasson C; Mongelard F; Lamba S; Bardelli A; Bouvet P; Couvelard A; Courty J; Giraudo E; Cascone I
    Cancer Res; 2016 Dec; 76(24):7181-7193. PubMed ID: 27754848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma.
    Raineri F; Bourgoin-Voillard S; Cossutta M; Habert D; Ponzo M; Houppe C; Vallée B; Boniotto M; Chalabi-Dchar M; Bouvet P; Couvelard A; Cros J; Debesset A; Cohen JL; Courty J; Cascone I
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonist of nucleolin, N6L, inhibits neovascularization in mouse models of retinopathies.
    Darche M; Cossutta M; Caruana L; Houppe C; Gilles ME; Habert D; Guilloneau X; Vignaud L; Paques M; Courty J; Cascone I
    FASEB J; 2020 Apr; 34(4):5851-5862. PubMed ID: 32141122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
    Benedetti E; Antonosante A; d'Angelo M; Cristiano L; Galzio R; Destouches D; Florio TM; Dhez AC; Astarita C; Cinque B; Fidoamore A; Rosati F; Cifone MG; Ippoliti R; Giordano A; Courty J; Cimini A
    Oncotarget; 2015 Dec; 6(39):42091-104. PubMed ID: 26540346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.
    Xu C; Wang Y; Tu Q; Zhang Z; Chen M; Mwangi J; Li Y; Jin Y; Zhao X; Lai R
    Oncogene; 2019 Mar; 38(11):1832-1844. PubMed ID: 30356139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.
    Ponzo M; Debesset A; Cossutta M; Chalabi-Dchar M; Houppe C; Pilon C; Nicolas-Boluda A; Meunier S; Raineri F; Thiolat A; Nicolle R; Maione F; Brundu S; Cojocaru CF; Bouvet P; Bousquet C; Gazeau F; Tournigand C; Courty J; Giraudo E; Cohen JL; Cascone I
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin.
    Dhez AC; Benedetti E; Antonosante A; Panella G; Ranieri B; Florio TM; Cristiano L; Angelucci F; Giansanti F; Di Leandro L; d'Angelo M; Melone M; De Cola A; Federici L; Galzio R; Cascone I; Raineri F; Cimini A; Courty J; Giordano A; Ippoliti R
    J Cell Physiol; 2018 May; 233(5):4091-4105. PubMed ID: 28941284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation.
    Chalabi-Dchar M; Cruz E; Mertani HC; Diaz JJ; Courty J; Cascone I; Bouvet P
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
    Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
    Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
    Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
    Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleolin mediates the antiangiogenesis effect of the pseudopeptide N6L.
    Birmpas C; Briand JP; Courty J; Katsoris P
    BMC Cell Biol; 2012 Nov; 13():32. PubMed ID: 23146273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature.
    Fogal V; Sugahara KN; Ruoslahti E; Christian S
    Angiogenesis; 2009; 12(1):91-100. PubMed ID: 19225898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivalent cationic pseudopeptide polyplexes as a tool for cancer therapy.
    Diamantopoulou Z; Gilles ME; Sader M; Cossutta M; Vallée B; Houppe C; Habert D; Brissault B; Leroy E; Maione F; Giraudo E; Destouches D; Penelle J; Courty J; Cascone I
    Oncotarget; 2017 Oct; 8(52):90108-90122. PubMed ID: 29163814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
    Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
    Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.
    Destouches D; El Khoury D; Hamma-Kourbali Y; Krust B; Albanese P; Katsoris P; Guichard G; Briand JP; Courty J; Hovanessian AG
    PLoS One; 2008 Jun; 3(6):e2518. PubMed ID: 18560571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins.
    Destouches D; Page N; Hamma-Kourbali Y; Machi V; Chaloin O; Frechault S; Birmpas C; Katsoris P; Beyrath J; Albanese P; Maurer M; Carpentier G; Strub JM; Van Dorsselaer A; Muller S; Bagnard D; Briand JP; Courty J
    Cancer Res; 2011 May; 71(9):3296-305. PubMed ID: 21415166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.
    Guo K; Cui J; Quan M; Xie D; Jia Z; Wei D; Wang L; Gao Y; Ma Q; Xie K
    Clin Cancer Res; 2017 Feb; 23(3):687-696. PubMed ID: 27449499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis.
    Husain K; Centeno BA; Coppola D; Trevino J; Sebti SM; Malafa MP
    Oncotarget; 2017 May; 8(19):31554-31567. PubMed ID: 28404939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
    Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
    Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.